Capital Fund Management S.A. Alnylam Pharmaceuticals, Inc. Transaction History

Capital Fund Management S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$143.31 - $247.0 $1.64 Million - $2.83 Million	11,454 Added 37.72%	41,821 $10.2 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $4.45 Million - $6.02 Million	30,367 New	30,367 $4.54 Million
Q2 2020 Aug 13, 2020	SELL	$104.21 - $156.44 $868,277 - $1.3 Million	-8,332 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$93.12 - $133.99 $775,875 - $1.12 Million	8,332 New	8,332 $906,000
Q4 2018 Feb 13, 2019	SELL	$62.67 - $88.33 $321,309 - $452,867	-5,127 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$87.52 - $122.67 $302,206 - $423,579	3,453 Added 206.27%	5,127 $449,000
Q4 2017 Feb 09, 2018	BUY	$114.49 - $139.98 $191,656 - $234,326	1,674	1,674 $213,000

643

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.